Weiss Louis M
Division of Infectious Diseases, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Room 504 Forchheimer Building, Bronx, New York, 10461, USA.
Expert Opin Pharmacother. 2002 Aug;3(8):1109-15. doi: 10.1517/14656566.3.8.1109.
Human infections with Babesia species, in particular Babesia microti, are tick-borne illnesses that are being recognised with increased frequency. Coinfection with ehrlichiosis and Lyme disease is also being recognised as an important feature of these tick-borne illnesses. Despite the superficial resemblance of Babesia to malaria, these piroplasms do not respond to chloroquine or other similar drugs. However, the treatment of babesiosis using a clindamycin-quinine combination has been successful. Data in animal models and case-reports in humans have suggested that an atovaquone-azithromycin combination is also effective. This was confirmed in a recent prospective, open, randomised trial of clindamycin-quinine versus azithromycin-atovaquone. This paper reviews the literature on the treatment of human babesiosis and the animal models of these human pathogens.
人类感染巴贝斯虫属，尤其是微小巴贝斯虫，是一种通过蜱传播的疾病，其被识别的频率越来越高。与埃立克体病和莱姆病的共感染也被认为是这些蜱传播疾病的一个重要特征。尽管巴贝斯虫与疟原虫表面相似，但这些梨形虫对氯喹或其他类似药物无反应。然而，使用克林霉素-奎宁联合治疗巴贝斯虫病已取得成功。动物模型数据和人类病例报告表明，阿托伐醌-阿奇霉素联合用药也有效。这在最近一项关于克林霉素-奎宁与阿奇霉素-阿托伐醌的前瞻性、开放性、随机试验中得到了证实。本文综述了关于人类巴贝斯虫病治疗及这些人类病原体动物模型的文献。
